Edgewise Therapeutics (EWTX) vs Ionis Pharmaceuticals (IONS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Edgewise Therapeutics (EWTX) has outperformed Ionis Pharmaceuticals (IONS) over the past year, gaining 76.0% versus a loss of 65.1%. Over five years, EWTX leads with a +95.8% price change compared with -8.5% for IONS. Ionis Pharmaceuticals is the larger company by market cap ($4.43 billion vs $4.37 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EWTX | IONS |
|---|---|---|
| Share price | $39.91 | $26.58 |
| Market cap | $4.37B | $4.43B |
| 1-day change | -3.07% | -2.35% |
| YTD return | +60.81% | -66.40% |
| 1-year return | +76.03% | -65.07% |
| 5-year return | +95.80% | -8.50% |
| P/E ratio (TTM) | 4.76 | — |
| EPS (TTM) | $8.38 | $-3.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $943.71M |
| Revenue growth (YoY) | — | +33.83% |
| Net income (latest FY) | $-167.79M | $-381.39M |
| Gross margin | — | 98.31% |
| Operating margin | — | -40.45% |
| Net margin | — | -40.41% |
| 52-week high | $48.78 | $86.74 |
| 52-week low | $19.76 | $26.53 |
| Distance from 52-week high | -18.19% | -69.36% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +38.88% | +155.19% |
| Average volume | 1.53M | 3.91M |
| Shares outstanding | 109.48M | 166.55M |
| Employees | 133 | 1,485 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EWTX has outperformed IONS by 141.1 percentage points over the past year.
About Edgewise Therapeutics
EWTX stock →Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.
Health Care · Biotechnology: Pharmaceutical Preparations · 133 employees
About Ionis Pharmaceuticals
IONS stock →Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA).
Health Care · Biotechnology: Pharmaceutical Preparations · 1,485 employees
EWTX vs IONS FAQ
Which is bigger, Edgewise Therapeutics or Ionis Pharmaceuticals?
Ionis Pharmaceuticals (IONS) is larger, with a market capitalization of $4.43B compared with $4.37B for Edgewise Therapeutics (EWTX).
Which stock has performed better over the past year, EWTX or IONS?
EWTX returned +76.03% over the past 12 months, compared with -65.07% for IONS (price return, excluding dividends). Past performance does not predict future results.
Are Edgewise Therapeutics and Ionis Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.